Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, schizophrenia, diabetes, ADHD and chronic migraine.

Latest News

Dec 15, 2014

Heptares’ Extends Global Patent Protection For GPCR-Focused Drug Discovery Platform With Grant Of Core Patents In The United States

Nov 20, 2014

Heptares Orphan Disease Programme Awarded Grant From The UK Biomedical Catalyst


Jan 10-11, 2015
East/West CEO Conference
San Francisco, USA
Presenting: Dan Grau

Jan 12-15, 2015
JPMorgan Healthcare Conference
San Francisco, CA, USA
Attending: Malcolm Weir, Dan Grau

© 2012-2014 Heptares Therapeutics